Britain and America have finalized a important bilateral deal that will keep zero import taxes on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on drugs through the NHS. This commitment ensures that duties on these crucial exports will remain at zero for a period of three years.
This agreement comes after recent threats to significantly raise import taxes on patented drug products, with potential rates discussed as high as double the cost.
"This deal between the United Kingdom strengthens the worldwide climate for cutting-edge drugs and introduces much-needed balance to transatlantic pharmaceutical trade," an announcement noted.
Commercial Impact
Medicines are one of the UK's most significant exports to the US, which is clearly the biggest destination for leading companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months leading up to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This amount represented a significant portion of total UK exports in that period.
"This deal protects employment, stimulates funding and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement entails several specific pledges from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount drug companies must refund to the NHS to stay within budget will be restricted at 15%. Previously, rebates exceeded 20%.
Recent Tensions
The deal takes place against a protracted dispute between the drug companies and the British authorities over spending levels and regulatory access.
These tensions were heightened by assertions that US customers were paying significantly more for the identical medicines than patients in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been paused or scrapped, while major investments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
